Inhibrx, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 78.71 million compared to USD 48.92 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 1.12 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.02 USD | -47.17% | -47.54% | -52.58% |
05-31 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index | CI |
05-31 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
-52.58% | 1.79B | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+0.99% | 22.48B | |
-9.44% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- INBX Stock
- News Inhibrx, Inc.
- Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024